The pathophysiology of acute respiratory distress syndrome (ARDS) includes the
accumulation of protein-rich pulmonary edema in the air spaces and interstitial areas of the …

Background Dexamethasone decreases mortality in coronavirus disease 2019 (COVID-19)
patients on intensive respiratory support (IRS) but is of uncertain benefit if less severely ill …

Sepsis is a major cause of death worldwide, not least because complex interventions need
to be provided within a short window of opportunity. Evidence-based guidelines for the …

Purpose Although there is evidence supporting the benefits of corticosteroids in patients
affected with severe coronavirus disease 2019 (COVID-19), there is little information related …

Clinical and molecular heterogeneity are common features of human disease.
Understanding the basis for heterogeneity has led to major advances in therapy for many …

Since the start of the SARS-CoV-2 pandemic, refractory and relentless hypoxia as a
consequence of exuberant lung inflammation and parenchymal damage remains the main …

Background Despite evidence associating inflammatory biomarkers with worse outcomes in
hospitalized adults with COVID-19, trials of immunomodulatory therapies have met with …

OBJECTIVES: COVID-19 is a heterogenous disease. Biomarker-based approaches may
identify patients at risk for severe disease, who may be more likely to benefit from specific …

Background The clinical heterogeneity of COVID-19 suggests the existence of different
phenotypes with prognostic implications. We aimed to analyze comorbidity patterns in …

Background: The coronavirus disease 2019 (COVID-19) pandemic has put significant
pressure on hospitals and in particular on intensive care units (ICU). Some patients develop …